|Bid||2.3000 x 1800|
|Ask||2.3100 x 1400|
|Day's Range||2.2700 - 2.3500|
|52 Week Range||1.5550 - 21.6900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||0.46|
|Earnings Date||Mar 16, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.33|
Subscribe to Yahoo Finance Plus to view Fair Value for CYT
The Petri Dish is a roundup of news that may get otherwise overlooked amid the influx of health care happenings. This week: Cyteir pauses development of cancer drug, Pfizer vet joins Watertown biotech and CEO steps down from Evelo Biosciences.
LEXINGTON, Mass., August 08, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent operational highlights.
LEXINGTON, Mass., August 01, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022.